Strongbridge Biopharma (SBBP) – Momentum Movers
-
Strongbridge Biopharma (SBBP) PT Raised to $17 at Cantor Fitzgerald
-
Strongbridge Biopharma (SBBP) climbs 42% after announcing results from Phase 3 study evaluating RECORLEV for treatment of endogenous Cushing’s syndrome
Back to SBBP Stock Lookup